Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetyl-L-Leucine for GM2 gangliosidosis
2018-004406-25Phase 2Completed
- Sponsor
- IntraBio
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levacetylleucine in GM2 gangliosidosis, Tay-Sachs disease (TSD) and Sandhoff disease, sponsored by IntraBio. Primary endpoint: Clinical Impression of Change in Severity. Started Jan 2019; status: completed.
02
Drugs
levacetylleucine
03
Conditions
GM2 gangliosidosisTay-Sachs disease (TSD)Sandhoff disease
Beyond the preview
Go deeper on 2018-004406-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004406-25.